SER - Serina Therapeutics, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

SER

SERINA THERAPEUTICS, INC.

AMEX

$2.45

▲ UP 10.36% (0.23)

KEY STATISTICS

Market Cap$33.29 M

52w High$5.83

52w Low$1.22

Dividend Yield—

Frequency—

P/E-1.30

Volume74.44K

Shares Out.15.00M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Steven A. Ledger

COMPENSATION 2026

Salary$450,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$637,500

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 28, 2018

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 18, 2026

DayWednesday

Rev. Est.—

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2024-03-15	Reverse	7:250
2015-05-06	Forward	16:15
2014-05-07	Forward	11:10
2012-05-04	Forward	5:4
2011-09-26	Forward	4:1

PRICE

$2.45 ▲ UP 10.36% (+$0.23)

OVERLAYS

About Serina Therapeutics, Inc.

https://serinatherapeutics.com ↗

Serina Therapeutics, Inc. develops drugs for neurological diseases and pain, including Parkinson's, epilepsy, and infectious diseases, with lead candidates like SER 252, SER 227, SER 214, and SER 228.

INDUSTRY

Biotechnology

A PRODUCT SERINA THERAPEUTICS, INC. IS KNOWN FOR

SER-252 (POZ-apomorphine)

SER-252 is an investigational, lead therapy for advanced Parkinson's, using the POZ Platform™ to deliver continuous apomorphine, with a Phase 1b trial enrolling its first patient as of February 2026.